Skip to content

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Joseph Mallon, Ph.D.

Joe’s practice includes intellectual property due diligence, Patent Office appeals, preparation and prosecution of patent applications, and counseling on patent strategy, patent infringement and licensing issues. He represents clients in...

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Ryan E. Melnick, Ph.D.

Ryan E. Melnick is a partner in our San Diego Office. Dr. Melnick’s practice focuses on obtaining patent protection and providing counsel to pharmaceutical, biotechnology, and medical device companies. His...

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Kimberly J. Miller, Ph.D.

Dr. Kim Miller serves as a single point of contact for all IP-related matters her clients face. For more established companies, she easily adapts to their processes and procedures, blending...

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Agnes Juang, Ph.D.

Dr. Agnes Juang provides counsel and advice to innovators seeking to protect their inventions and to grow and monetize their IP assets. Her practice includes strategic global patent procurement, portfolio development...

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

William Zimmerman

Having served as lead counsel in over 100 pharmaceutical litigations, including cases involving “blockbuster” drugs like Lipitor and Nexium, William R. Zimmerman is widely recognized as one of the nation’s...

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Jane Dai, Ph.D.

With extensive knowledge in organic chemistry, Jane advises clients in life sciences, with a particular focus on small molecule and oligonucleotide pharmaceuticals. She has a deep understanding of the entire...

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Nathanael Luman, Ph.D.

Nathanael R. Luman, Ph.D., represents chemical and pharmaceutical companies in intellectual property matters. He is actively involved in Inter Partes Review (IPR) proceedings before the Patent Trial and Appeal Board....